What is the difference between wegovy and zepbound?

Background on WEGOVY and ZEPBOUND

WEGOVY [1] and ZEPBOUND [2] are two separate medications developed for weight management.

Primary Use Cases and Mechanisms

WEGOVY, containing Tirzepatide, is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. It works by mimicking the action of natural hormones to help reduce hunger and increase feelings of fullness, promoting weight loss [3].

On the other hand, ZEPBOUND, containing Tirzepatide-AMG 257, is not a well-documented medication, therefore, information is limited. AMG 257 is a selective inhibitor of human epidermal growth factor receptor 2 (HER2) tyrosine kinase.

Differences in Approval and Availability

WEGOVY (tirzepatide) has been approved by the FDA for the treatment of obesity, while ZEPBOUND doesn't appear to be an FDA-approved medication in the United States. Furthermore, there are multiple medications marketed for weight loss under generic or brand names not related to those above, with various active ingredients and effects.

Comparison in Clinical Trial Data

There is limited publicly available comparative data between these two medications. Tirzepatide, found in WEGOVY, demonstrated significant weight loss results in clinical trials compared to placebo. In contrast, there's no publicly available clinical trial or data release on ZEPBOUND.